Marked Increase in Bone Mineral Density with Oral Phosphate and Calcitriol in Tumour-induced Osteomalacia

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2023 Dec 6

PMID 38056928

Authors

Partha Pratim Chakraborty

Rana Bhattacharjee

Ajitesh Roy

Subhankar Chowdhury

Affiliations

Soon will be listed here.

Abstract

Patients with osteomalacia have a low bone mineral density (BMD) and are often misdiagnosed as osteoporosis. A marked increase in BMD is noticed following successful treatment of osteomalacia. The biochemical hallmark of tumour-induced osteomalacia (TIO) is hypophosphatemia. Patients with TIO often have severe hypophosphatemic osteomalacia and dual-energy X-ray absorptiometry may demonstrate low BMD. Surgical removal of the phosphatonin-secreting lesion restores serum phosphate, corrects osteomalacia and is associated with a dramatic increase in BMD. We report two patients with TIO and low BMD, who were treated with oral phosphate and calcitriol supplementation. The percentage increase in BMD at 33 months was as high as 94.3% in areas with the lowest BMD at baseline. The BMD at 33 months was higher than the +2SD of the population-specific reference ranges, a finding not reported in surgically treated patients with TIO. An intermittent rise in parathyroid hormone following oral phosphate supplementation might have resulted in such findings.

References

Sapir-Koren R, Livshits G . Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of fibroblast growth factor 23. Biofactors. 2014; 40(6):555-68. DOI: 10.1002/biof.1186. View

Kumar S, Diamond T . Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome. Bone Rep. 2020; 12:100276. PMC: 7235936. DOI: 10.1016/j.bonr.2020.100276. View

Lotz M, Zisman E, Bartter F . Evidence for a phosphorus-depletion syndrome in man. N Engl J Med. 1968; 278(8):409-15. DOI: 10.1056/NEJM196802222780802. View

Raisz L, Niemann I . Effect of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture. Endocrinology. 1969; 85(3):446-52. DOI: 10.1210/endo-85-3-446. View

Umphrey L, Whitaker M, Bosch E, Cook C . Clinical and bone density outcomes of tumor-induced osteomalacia after treatment. Endocr Pract. 2007; 13(5):458-62. DOI: 10.4158/EP.13.5.458. View

Bhambri R, Naik V, Malhotra N, Taneja S, Rastogi S, Ravishanker U . Changes in bone mineral density following treatment of osteomalacia. J Clin Densitom. 2006; 9(1):120-7. DOI: 10.1016/j.jocd.2005.11.001. View

. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2001; 17(1):1-45. View

Miyauchi A, Dinavahi R, Crittenden D, Yang W, Maddox J, Hamaya E . Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos. 2019; 14(1):59. PMC: 6551345. DOI: 10.1007/s11657-019-0608-z. View

Ejima E, Kiriyama T, Fujiyama K, Abe Y, Ashizawa K, Tominaga T . Cultured oncogenic osteomalacia tumor cells produce a factor(s) that inhibits osteocalcin production by osteoblastic cells. Oncol Rep. 2011; 4(6):1327-30. DOI: 10.3892/or.4.6.1327. View

10.

Miller P . Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am. 2012; 41(3):613-28. DOI: 10.1016/j.ecl.2012.05.005. View

11.

Guo Y, Zhou Y, Wu X, Tang C, Wang M, Mo Z . Changes in Bone Mineral Density Following Conventional Oral Phosphonate Treatment of Hypophosphatemic Osteomalacia: A Non-Randomized Controlled Study. Int J Gen Med. 2021; 14:7925-7931. PMC: 8593346. DOI: 10.2147/IJGM.S332534. View

12.

Colangelo L, Pepe J, Nieddu L, Sonato C, Scillitani A, Diacinti D . Long-term bone mineral density changes after surgical cure of patients with tumor-induced osteomalacia. Osteoporos Int. 2020; 31(7):1383-1387. DOI: 10.1007/s00198-020-05369-1. View

13.

Shane E, Parisien M, Henderson J, Dempster D, Feldman F, Hardy M . Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res. 1997; 12(9):1502-11. DOI: 10.1359/jbmr.1997.12.9.1502. View

14.

Matsumoto T, Sone T, Soen S, Tanaka S, Yamashita A, Inoue T . Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study. J Clin Endocrinol Metab. 2022; 107(10):e4222-e4231. PMC: 9516124. DOI: 10.1210/clinem/dgac486. View

15.

Saghafi M, Azarian A, Hashemzadeh K, Sahebari M, Rezaieyazdi Z . Bone densitometry in patients with osteomalacia: is it valuable?. Clin Cases Miner Bone Metab. 2014; 10(3):180-2. PMC: 3917579. View

16.

Basha B, Rao D, Han Z, Parfitt A . Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption. Am J Med. 2000; 108(4):296-300. DOI: 10.1016/s0002-9343(99)00460-x. View